Efficacy of Nipocalimab, a Novel Neonatal Fragment Crystallizable Receptor Blocker, as Measured Using Quantitative Myasthenia Gravis Assessment: Findings from the Phase 3 Placebo-controlled Vivacity-MG3 Study

Infections-related Safety Profile of Efgartigimod Alpha and Immunoglobulins in Myasthenia Gravis